Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection
Abstract
Efavirenz (EFV)- and dolutegravir (DTG)-based antiretroviral therapy (ART) is the former and current recommended regimen for treatment-naive individuals with human immunodeficiency virus type 1 (HIV-1). Whether they impact the immunological and neuropsychiatric profile differentially remains unclear.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 10, 2022
- Source ID
- 10.1093/cid/ciac466
Entities
People
- Bohyung Yoon
- Carlo Sacdalan
- Denise Hsu
- Donn Colby
- Eugène Kroon
- Jintanat Ananworanich
- Nittaya Phanuphak
- Phillip Chan
- Robert Paul
- Sandhya Vasan
- Serena Spudich
- Somchai Sriplienchan
- Suteeraporn Pinyakorn
- Victor G Valcour
Organizations
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- National Institute of Allergy and Infectious Diseases
- National Institute of Mental Health
- National Institute of Neurological Disorders and Stroke
- United States Department of Defense
- University of Amsterdam
- University of California, San Francisco
- University of Missouri–St. Louis
- Walter Reed Army Institute of Research
- Yale School of Medicine